SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2026	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2021
Restructuring Cost and Reserve [Line Items]
Advances to vendor amount			$ 3,115
Vendor advances in cash			2,615
Issuance of common shares paid for vendors advances			500
Amortization expense - vendor advances			256
Vendor advances			2,859
Amortization of Intangible Assets			160	$ 160
Intangible Assets, Net (Excluding Goodwill)			222	382
Impairment of intangible assets			$ 0	$ 0
Potentially dilutive securities			278,188	150,000
Deferred tax assets valuation allowance, percentage			100.00%	100.00%
Patent expenses			$ 1,929	$ 1,632
Research and developments costs			$ 810	82
Expected dividend yield			0.00%
Patents [Member]
Restructuring Cost and Reserve [Line Items]
Patent expenses			$ 134	45
IPO [Member]
Restructuring Cost and Reserve [Line Items]
Deferred offering costs			872	$ 482
Line of credit			$ 1,377
Restricted Stock Units (RSUs) [Member]
Restructuring Cost and Reserve [Line Items]
Unvested restricted stock			172,000
Forecast [Member]
Restructuring Cost and Reserve [Line Items]
Amortization of Intangible Assets	$ 62	$ 160
Enviro Threapeutics Inc [Member]
Restructuring Cost and Reserve [Line Items]
Business Acquisition, Transaction Costs					$ 800